EA201792169A1 - 5'-замещенные нуклеозидные соединения - Google Patents

5'-замещенные нуклеозидные соединения

Info

Publication number
EA201792169A1
EA201792169A1 EA201792169A EA201792169A EA201792169A1 EA 201792169 A1 EA201792169 A1 EA 201792169A1 EA 201792169 A EA201792169 A EA 201792169A EA 201792169 A EA201792169 A EA 201792169A EA 201792169 A1 EA201792169 A1 EA 201792169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compounds
substituted nucleoside
connections
leukemia
Prior art date
Application number
EA201792169A
Other languages
English (en)
Inventor
Захид Квиоом Бондаи
Гиллермо С. Кортез
Карл Роберт Данке
Майкл Джон Гроган
Антонио Родригез Эргета
Джеймс Эндрю Джеймисон
Брайан Морган Уотсон
Тимоти Эндрю Вудс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201792169A1 publication Critical patent/EA201792169A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Abstract

Настоящее изобретение относится к новым 5'-замещенным нуклеозидным соединениям, к фармацевтическим композициям, содержащим такие соединения, и к способам применения указанных соединений для лечения рака, более конкретно, для лечения рака, в частности глиобластомы, меланомы, саркомы, рака желудка, рака поджелудочной железы, холангиокарциномы, рака мочевого пузыря, рака молочной железы, немелкоклеточного рака легких, лейкозов, включая острый миелоидный лейкоз, и лимфом.
EA201792169A 2015-05-04 2016-04-27 5'-замещенные нуклеозидные соединения EA201792169A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382225 2015-05-04
PCT/US2016/029475 WO2016178870A1 (en) 2015-05-04 2016-04-27 5'-substituted nucleoside analogs

Publications (1)

Publication Number Publication Date
EA201792169A1 true EA201792169A1 (ru) 2018-03-30

Family

ID=53177322

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792169A EA201792169A1 (ru) 2015-05-04 2016-04-27 5'-замещенные нуклеозидные соединения

Country Status (25)

Country Link
US (1) US9840532B2 (ru)
EP (1) EP3292128A1 (ru)
JP (2) JP6181889B1 (ru)
KR (1) KR20170132871A (ru)
CN (1) CN107580602A (ru)
AR (1) AR104326A1 (ru)
AU (1) AU2016258485A1 (ru)
BR (1) BR112017020336A2 (ru)
CA (1) CA2981097A1 (ru)
CL (1) CL2017002637A1 (ru)
CO (1) CO2017010727A2 (ru)
CR (1) CR20170443A (ru)
DO (1) DOP2017000255A (ru)
EA (1) EA201792169A1 (ru)
EC (1) ECSP17072987A (ru)
HK (1) HK1244007A1 (ru)
IL (1) IL254409A0 (ru)
MA (1) MA42036A (ru)
MX (1) MX2017014001A (ru)
PE (1) PE20180231A1 (ru)
PH (1) PH12017502002A1 (ru)
SG (1) SG11201708345XA (ru)
TN (1) TN2017000459A1 (ru)
TW (1) TWI615400B (ru)
WO (1) WO2016178870A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017017396A2 (pt) * 2015-02-24 2018-04-03 Pfizer derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
WO2018139181A1 (ja) * 2017-01-27 2018-08-02 国立大学法人 宮崎大学 抗がん剤、抗がん剤のスクリーニング方法、がんに対する有効性判定キット及びがんに対する有効性判定方法
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3665179B1 (en) 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN111542525B (zh) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
HUE059945T2 (hu) 2017-12-13 2023-01-28 Lupin Ltd Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
BR112020018636A2 (pt) 2018-03-14 2020-12-29 Prelude Therapeutics, Incorporated Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5)
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
LT3980417T (lt) 2019-06-10 2023-12-27 Lupin Limited Prmt5 inhibitoriai
CN114599361A (zh) 2019-10-22 2022-06-07 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
CN115135651A (zh) 2019-12-03 2022-09-30 鲁皮恩有限公司 作为prmt5抑制剂的被取代的核苷类似物
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147908A0 (en) 1999-08-27 2002-08-14 Icn Pharmaceuticals PYRROLO[2,3-d] PYRIMIDINE NUCLEOSIDE ANALOGS
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
EP2935242A2 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Methods of inhibiting prmt5
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
BR112017017396A2 (pt) * 2015-02-24 2018-04-03 Pfizer derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos

Also Published As

Publication number Publication date
US9840532B2 (en) 2017-12-12
US20160326208A1 (en) 2016-11-10
JP6181889B1 (ja) 2017-08-16
WO2016178870A1 (en) 2016-11-10
IL254409A0 (en) 2017-11-30
TWI615400B (zh) 2018-02-21
JP2017525667A (ja) 2017-09-07
PE20180231A1 (es) 2018-01-31
MA42036A (fr) 2018-03-14
AR104326A1 (es) 2017-07-12
KR20170132871A (ko) 2017-12-04
JP2017125029A (ja) 2017-07-20
DOP2017000255A (es) 2018-01-15
TN2017000459A1 (en) 2019-04-12
ECSP17072987A (es) 2018-02-28
EP3292128A1 (en) 2018-03-14
CL2017002637A1 (es) 2018-04-20
PH12017502002A1 (en) 2018-03-26
CN107580602A (zh) 2018-01-12
TW201712022A (zh) 2017-04-01
SG11201708345XA (en) 2017-11-29
CO2017010727A2 (es) 2018-01-31
CR20170443A (es) 2017-11-07
HK1244007A1 (zh) 2018-07-27
CA2981097A1 (en) 2016-11-10
AU2016258485A1 (en) 2017-10-12
BR112017020336A2 (pt) 2019-05-14
MX2017014001A (es) 2018-03-16

Similar Documents

Publication Publication Date Title
EA201792169A1 (ru) 5'-замещенные нуклеозидные соединения
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
EA201590987A1 (ru) Соединения и способы их применения
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201590997A1 (ru) Соединения и способы их применения
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
EA201892769A2 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
EA201790603A1 (ru) Ингибиторы гистондеметилазы
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2018006155A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
EA201790604A1 (ru) Ингибиторы гистондеметилазы
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
EA202090270A1 (ru) Новые замещенные производные ксантина